Clinical Report: Incretin Trials Often Exceed Muscle-Loss Benchmarks

Overview

Revise to specify that muscle loss is particularly noted in incretin-based interventions.

Background

Understanding the impact of weight-loss interventions on muscle mass is crucial, particularly as obesity rates rise and effective treatments are sought. Muscle loss can lead to sarcopenic obesity, which poses additional health risks. This review highlights the need for careful consideration of muscle preservation in weight-loss strategies.

Data Highlights

No numerical data available for tabulation.

Key Findings

• Muscle-related losses exceeded benchmarks in about 68% of incretin-based interventions.
• Among studies using bioelectrical impedance analysis or dual-energy x-ray absorptiometry, 65% exceeded the 25% muscle-loss benchmark.
• All studies using computed tomography or magnetic resonance imaging exceeded the 15% skeletal muscle benchmark.
• Higher-efficacy therapies like semaglutide and tirzepatide were linked to greater muscle-related losses compared to liraglutide or dulaglutide.
• Half of nonpharmacologic comparator interventions also exceeded muscle-loss benchmarks despite smaller overall weight reductions.

Clinical Implications

Clinicians should be aware that significant muscle loss can occur with weight-loss interventions, including pharmacologic and lifestyle approaches. Monitoring muscle mass and function is essential to mitigate potential adverse effects associated with weight loss.

Conclusion

The findings underscore the importance of evaluating muscle preservation in weight-loss strategies, as muscle loss may not be confined to specific therapies but rather a broader physiological response to weight reduction.

References

1. Batsis JA, et al., Annals of Internal Medicine, 2026 -- Incretin Trials Often Exceed Muscle-Loss Benchmarks
2. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Impact of Obesity and IL-6 on Amino Acid and Protein Metabolism
3. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Diminished Insulin-Mediated Regulation of Plasma Lipid Uptake
4. conexiant — Side Effects: Turns Out, Never Mind
5. Therapeutic Approaches to Preserve Muscle Mass Amidst Advances in Pharmacological Weight Reduction